Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports. Several other ...

Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...

Leap Therapeutics (LPTX) stock extends losses as Baird downgrades citing disappointing trial data the company posted for its lead asset sirexatamab. Read more here.

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...

Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with ...

Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.

Leap Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -70.45%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...